Print
Email
Print Edition Stories
MHT's Marc Songini: Mass. bio firms prep for lifting of stem cell ban
Lab and research equipment provider PerkinElmer Inc. is collaborating with the Republic of Korea’s Sangmyung University for drug research.
This week, Waltham-based PerkinElmer (NYSE: PKI) announced it would be working with the staff at Sangmyung University on cutting-edge G-protein coupled receptor (GPCR) research projects. In a statement, the company claimed that GPCRs are connected with 30 percent of addressable diseases, and that they also are a key focus in drug discovery efforts.
The research will involve applying PerkinElmer’s AequoScreen aequorin assay technology to the effort. These cell-based aequorin assays are sensitive and flexible and can detect GPCR activation, the company claimed. They also offer some positive aspects over conventional fluorescence based dyes — including the generation of fewer false positives, simpler protocol and increased assay windows.
Sangmyung University will use AequoScreen to establish an academic GPCR screening facility with the Korea Chemical Bank, a national library of over 100,000 small molecule compounds. Researchers will use aequorin technology in a series of nationwide GPCR screening campaigns and drug discovery programs in Korea.
PerkinElmer reported revenue of almost $2 billion in 2008. It has approximately 8,500 employees in more than 150 countries.
Last month, purchased Opto Technology Inc., an Illinois-based supplier of lighting components and subsystems that use light-emitting diodes (LEDs).
Opto Technology’s optical subsystems will be added to PerkinElmer’s own portfolio of LED components to supply original equipment manufacturers serving the health, safety and security markets, PerkinElmer claimed.
RSS Feeds
Comments
Please Login/Register to post comments.
No comments have been added or approved.